AbbVie (ABBV) Stock Analysis
NYQ · Healthcare · Drug Manufacturers - General
$264.58
+0.30 (+0.11%)
ABBV Interactive Price Chart & Trading Signals
ABBV Stock Snapshot — Valuation, Risk & Technical Signals
ABBV Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$467.54B
P/E Ratio
74.53
Forward P/E
16.26
PEG Ratio
0.54
P/B Ratio
-78.77
EPS
$3.55
Dividend Yield
2.62%
52W Range
$190.75 – $269.39
Beta
0.28
Volume
0.2M
ROE
—
Profit Margin
9.8%
Revenue Growth
10.2%
Gross Margin
72.8%
EV/EBITDA
17.28
Analyst Target
$278.56
The trailing price-to-earnings ratio stands at 74.5x. Forward P/E of 16.3x implies earnings expansion expected. EV/EBITDA sits at 17.28x. Market capitalization is $467.54B. Revenue is growing at 10.2% on a trailing basis. Earnings are expanding at 290.4%. Profit margins are 9.8%. Beta of 0.28 indicates defensive profile.
Analyst Consensus
Recommendation
Buy
Low Target
$200.00
Mean Target
$278.56
High Target
$328.00
Based on 27 analysts
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationNon-zero inputs
4/5Counts non-zero values for price, P/E, beta, macro risk, and revenue growth; zero may mean unavailable or be a genuine zero.
AbbVie Inc. (ABBV) trades above our multi-model fair value estimate of $185.22 by approximately 30.0%. Trailing P/E: 74.5x. Profitability signals include profit margin of 9.8%. Recent growth metrics show revenue growth of 10.2% and earnings growth of 290.4%. Risk profile: defensive beta of 0.28. Consensus: buy.
Valuation, Growth & Risk
Valuation
Overvalued
P/E 74.5x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 10.2%
Revenue is outpacing the market.
Risk
Low
Beta 0.28
Movement is likely to track the broader market.
Valuation Snapshot
AbbVie Inc. (ABBV) trades above our multi-model fair value estimate of $185.22 by approximately 30.0%. The trailing price-to-earnings ratio stands at 74.5x. Forward P/E of 16.3x suggests earnings compression ahead. Price-to-sales is 7.3x. EV/EBITDA sits at 17.3x. Market capitalization is $467.54B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 10.2% on a trailing basis. Earnings are expanding at 290.4%. Profit margins are 9.8%. Return on assets is 10.5%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 0.28 indicates defensive profile. Net debt position is $64.32B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $278.56 implies 5.3% upside. Target range spans $200.00 to $328.00. 27 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, and market cap: Yahoo Finance (may be delayed)
- P/E, EPS, revenue, and debt: Yahoo Finance fundamentals
- Analyst estimates: Yahoo Finance (coverage and update times vary)
- Insider transactions: Yahoo Finance (reporting may be delayed)
QuantSoar Model (Derived)
- Fair value: available outputs from seven models; outliers are filtered using MAD (k=3.5), then combined with fixed model weights.
- Margin of Safety = (Fair Value − Displayed Price) / Displayed Price × 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation (up to ±25) + Whale sentiment (up to ±10) + Insider buying (+5) + Macro risk (up to ±10) + Technical signal (up to ±10). Analyst consensus is separate.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
ABBV Overvalued
AbbVie Inc. (ABBV) trades above our multi-model fair value estimate of $185.22 by approximately 30.0%.
Frequently Asked Questions
ValuationIs ABBV stock overvalued right now?
ValuationWhat is ABBV fair value based on current fundamentals?
RiskHow risky is ABBV compared with other stocks?
GrowthIs ABBV still growing?
AnalystWhat do analysts think about ABBV?
DividendDoes ABBV pay a dividend?
CatalystWhat could change the investment case for ABBV?
Related Stocks
JNJ
Peer stock in Healthcare
View analysis →PFE
Peer stock in Healthcare
View analysis →MRK
Peer stock in Healthcare
View analysis →ABBV vs JNJ
Side-by-side valuation, risk, and growth comparison
Compare →ABBV vs PFE
Side-by-side valuation, risk, and growth comparison
Compare →Healthcare
Explore top stocks in this sector
Explore sector →
About the Author
Phasakorn Traklang (Peach) — Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: Tax treatment can depend on tax residence, account type, and tax year. This information is general and is not personal tax or investment advice. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.